Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.
Approval Alert | Zanidatamab in Metastatic HER2-Positive Biliary Tract Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC
4
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
5
